In the above-named article by McKee A, Al-Khazaali A, and Albert SG (J Endocr Soc. 2020;4(5):1–17; doi: 10.1210/jendso/bvaa037), the following transcriptional error occurred in the published paper: “For the cardiovascular MACE event rate of Wiviott et al (reference 10), the event rate in drug vs placebo should be 756 vs 803 instead of 594 vs 663. Additionally, Table 1, page 4 Perkovic, should read “4-point MACE. There were small changes in the calculated relative rates and rate differences which are not statistically different from our original calculations.”
The authors have made changes in the Figure 1A, abstract, text, Table 1 page 4, and calculations.
Figure 1A is attached.
The corrected line in the abstract now reads:
“Main Outcome Measures. Six trials of GLP-1 RA (51 762 subjects) and 4 trials of SGLT2i (33 457 subjects) showed both drug classes reduced MACE and CVD versus controls, with neither class preferred (comparison GLP1-RA vs SGLT2i: relative rate [rr] MACE 1.04, 95% confidence interval [CI] 0.94, 1.16, P = ns; rr CVD 1.04, 95% CI 0.87, 1.24, P = ns).”
The corrected line in the text, from page 8 in the Cardiovascular outcomes section, now reads:
“Both classes of drug were associated with improvements in MACE compared with controls for the GLP-1 RA (relative rate [rr] 0.91, 95% confidence interval [CI] 0.87, 0.96, P < 0.001) and for SGLT2i (rr 0.87, CI 0.82, 0.93, P < 0.001) (Fig. 1A). There was no difference in the rates of MACE between the GLP-1 RA and SGLT2i (rr comparison 1.04, CI 0.94, 1.16, P = ns (Fig. 1A).”
The corrected portion of Table 1, on page 4, now reads:
| Study | Marso (LEADER) 2016 Mann 2017 |
Pfeffer (ELIXA) 2015 | Marso (SUSTAIN-6) 2016 | Holman (EXSCEL) 2017 | Gerstein (REWIND) 2019 | Husain (Pioneer) 2019 | Zinman (EMPA- REG) 2015 | Neal (CANVAS) 2017 | Perkovic (CREDENCE) 2019 | Wiviott (DECLARE- TIMI58) 2018/ Mosenzon 2019 |
|---|---|---|---|---|---|---|---|---|---|---|
| Change in weight, Kg, drug vs. control | 2.3 (0.13) | −0.7 (0.10) | −4.35 (0.30) | −1.27 (nr) | −1.46 (0.11) | −3.4 | −1.98 (0.19) | −1.6 (0.05) | −0.8 (0.17) | −1.8 (0.08) |
| Primary cardiovascular end-point, number of subjects (drug/ control) | 3-point MACE | 4-point MACE | 3-point MACE | 3-point MACE | 3-point MACE | 3-point MACE | 3-point MACE | 3-point MACE | 4-point MACE | 3-point MACE |
| Cardiovascular MACE drug/ control (n/n) | 608/694 | 406/399 | 108/146 | 839/905 | 594/663 | 61/76 | 490/282 | 538/473 | 273/361 | 756/803 |